Inaktiver Wert

Andere Sprachen Aimmune Therapeutics, Inc.

Aktien

A14X6J

US00900T1079

AIMT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIAÂ« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years	10.11.22
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients	13.10.22
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology	16.02.22
Aimmune Therapeutics, Inc. Presents New PALFORZIA?	12.11.21
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis	08.06.21
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3	25.02.21
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	22.01.21
Aimmune Therapeutics : European Commission approves first treatment for peanut allergy	05.01.21
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	22.12.20
Bourse Zurich: la nouvelle variante du coronavirus effraie le marché	21.12.20
Bourse Zurich: toujours plombée par les craintes sur la nouvelle souche de virus	21.12.20
Bourse Zurich: les craintes sur la nouvelle souche de virus l'emportent	21.12.20
Nestlé fait une percée pour traiter l'allergie aux arachides	21.12.20
Bourse Zurich: la mutation du coronavirus effraie les investisseurs	21.12.20
Bourse Zurich: ambiance minée par la mutation du coronavirus	21.12.20
Nestlé: Palforzia contre les allergies aux arachides agréé par l'UE	21.12.20
Aimmune Therapeutics : European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU	21.12.20
European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for Peanut Allergy in the EU	21.12.20
Nestle S A : shrugs off COVID-19 impact thanks to pet food and health nutrition	21.10.20
Nestlé: des ventes solides aux 9 premiers mois de l'année	21.10.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aimmune Therapeutics, Inc.

Aktien

A14X6J

US00900T1079

AIMT

Andere Sprachen

Filter